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right and left heart catheterisations and more 
subtle imaging techniques12 might be able to better 
diff erentiate pulmonary hypertension due to left heart 
disease from PAH.
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Emerging respiratory viral infections: MERS-CoV and infl uenza
Each year, the world faces the rising burden of viral 
respiratory infections. These infections are of major 
importance to public health because of the lack of 
specifi c therapeutic and preventive measures, and, 
more specifi cally, the lack of vaccines for most of these 
viruses.1
In 2013, the emergence of three new respiratory 
viruses—varian infl uenza virus (H3N2v), H7N9, and 
Middle East Respiratory Syndrome coronavirus (MERS-
CoV)—was of particular concern. These viruses all have 
the potential to cause widespread pandemics with 
substantial morbidity and mortality. The two infl uenza 
viruses (variant infl uenza virus and H7N9) were reported 
to cause, potentially severe, disease in human beings. 
Infection with MERS-CoV was initially described in 
a patient from Saudi Arabia and then retrospectively 
identifi ed in patients from Zarqa, Jordan.2,3 As of 
Dec 2, 2013, 163 cases of infection with MERS-CoV 
have been reported, with 71 fatalities.4 MERS-CoV can 
cause sporadic infection, infection among families, 
and, of particular concern, infection among health-
care workers.5 The largest outbreak of MERS-CoV was 
described in Al-Hasa, the eastern province of Saudi 
Arabia.5 Fever and cough was present in most cases, 
with shortness of breath in almost half of all cases, 
and gastrointestinal symptoms in about a third. 
A study of the largest reported outbreak of MERS-
CoV6 estimated the median incubation period to be 
5·2 days (95% CI 1·9–14·7), and reported a high rate 
of person-to-person transmission in 21 of 23 cases 
in health-care settings.6 Case-fatality rate was high 
(65%) in this outbreak.7 Of more than 417 household 
and health-care contacts, symptoms of MERS-CoV 
developed in only seven people.6 A subsequent large-
scale phylogenetic analysis of 21 genome sequences 
and inclusion of the previous nine published MERS-
CoV genomes showed that multiple introductions of 
MERS-CoV and lower R0 values were possible.7 Thus 
MERS-CoV has not yet reached pandemic potential. 
Transmission within Saudi Arabia was consistent with 
movement of an animal reservoir, animal products, 
or infected people. The source of the infection has 
yet to be identifi ed, although bats and camels have 
been implicated.
A clinical and epidemiological analysis of 47 cases 
showed that infection with MERS-CoV occurred 
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predominantly in men,5 although this fi nding did 
not hold after an interim analysis of 133 cases.8 Most 
patients who were initially infected with MERS-CoV 
had underlying comorbid medical conditions and 
laboratory testing showed that most of these cases 
had raised concentrations of lactate dehydrogenase 
and aspartate aminotransferase associated with 
thrombocytopenia and lymphopenia.5 In preparation 
for the Hajj this year, the largest recurring religious 
mass gathering worldwide, the Saudi Ministry 
of Health recommended that certain individuals 
postpone their participation. Groups particularly at 
risk from infection include pregnant women, children 
younger than 12 years, adults older than 65 years, and 
those with chronic or acute diseases. The concern over 
the pandemic potential of MERS-CoV was estimated in 
two recent publications.9 In one optimistic view,9 the 
estimated MERS-CoV R0 was 0·69 compared with the 
R0 for prepandemic severe acute respiratory syndrome-
coronavirus of 0·80. This optimistic estimate 
downplayed the possibility of a MERS-CoV pandemic, 
which supported the recommendations of the Third 
Meeting of the International Health Regulations 
Emergency Committee,10 that MERS-CoV does not 
warrant international measures to curtail Hajj-related 
travel. Sporadic cases MERS-CoV continue to be 
reported, and thus continued vigilance and further 
studies are needed to close the knowledge gap in 
MERS-CoV epidemiology and clinical presentations.5
A novel avian-origin infl uenza A virus, H7N9, 
was initially described in human beings in China on 
March 30, 2013. At that time, three patients developed 
fatal pneumonia and were subsequently diagnosed as 
infected with H7N9.11,12 Since this initial description, 
H7N9 has resulted in 139 infections and 45 fatalities.13 
Review of the initial 111 patients with H7N9 infection14 
showed a high rate of admission to intensive-care units 
(76·6%) with a mortality rate of 27%. Infected patients 
were older adults with a median age of 61 years, with 
twice as many men infected than women. It is also 
interesting to note that most patients infected with 
H7N9 had a pre-existing medical condition. Subsequent 
analysis of 136 laboratory confi rmed cases showed a 
mortality bias toward men older than 50 years.15 Of the 
total cases, 7% were reported in individuals younger 
than 20 years, with no fatal cases in this age group.15
The emergence of these viral respiratory infections 
(H7N9 and MERS-CoV) showed a similar initial pattern: 
the predominant involvement of older men and the 
presence of comorbid conditions in most cases. This 
pattern seems to be due to recognition bias, because 
younger cases are now being identifi ed who have 
no underlying medical conditions. In facing future 
challenges of emerging respiratory viruses such as 
infl uenza there is a clear need for the development of 
eff ective infl uenza vaccines that target the conserved 
antigenic structures of infl uenza virus. Continued 
contact of humans with animals creates an added risk 
of development of zoonotic diseases, adaptation of 
the new virus rendering it infectious to humans, and 
possible effi  cient transmission of these viruses among 
the human population. 
The emergence of respiratory viruses that cause 
signifi cant disease in human beings is a major risk 
to the global economy and the health of the human 
population. The potential eff ect of newly discovered 
viruses calls for a better understanding of the human–
animal interface, the development of rapid diagnostic 
tests, and eff ective antiviral and immunomodulatory 
therapies.13 The eradication of respiratory viruses is not 
possible and thus the development of eff ective vaccines 
directed against the conserved antigens of these viruses 
would be extremely welcome. Finding predictors of 
severe disease and the initiation of antiviral drugs early 
in the course of many respiratory viral infections might 
prove to be benefi cial.
2013 Research Highlights
www.thelancet.com/respiratory   Vol 2   January 2014 25
Jaff ar A Al-Tawfi q, *Ziad A Memish
Saudi Aramco Medical Services Organization, Saudi ARAMCO, 
Dhahran, Saudi Arabia (JAA-T); Department of Medicine, Indiana 
University School of Medicine, Indianapolis, IN, USA (JAA-T); 
Global Centre for Mass Gathering Medicine, Public Health 
Directorate, Ministry of Health, Riyadh 11176, Saudi Arabia (ZAM); 
and Department of Medicine, Al-Faisal University, Riyadh 11176, 
Saudi Arabia (ZAM)
zmemish@yahoo.com 
We declare that we have no confl icts of interest.
1 WHO. Research needs for the Battle against Respiratory Viruses (BRaVe). 
http://www.who.int/infl uenza/patient_care/clinical/BRaVe_Research_
Agenda_2013.pdf (accessed Nov 18, 2013).
2 Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 
Isolation of a novel coronavirus from a man with pneumonia in Saudi 
Arabia. N Engl J Med 2012; 367: 1814–20.
3 Hijawi B, Abdallat M, Sayaydeh A, et al. Novel coronavirus infections in 
Jordan, April 2012: epidemiological fi ndings from a retrospective 
investigation. East Mediterr Health J 2013; 19 (suppl 1): S12–18.
4 WHO. Middle East respiratory syndrome  coronavirus (MERS-CoV) - 
update. http://www.who.int/csr/don/2013_12_02/en/index.html 
(accessed Dec 7, 2013).
5 Assiri A, Al-Tawfi q JA, Al-Rabeeah AA, et al. Epidemiological, demographic, 
and clinical characteristics of 47 cases of Middle East respiratory syndrome 
coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 
2013; 13: 752–61.
6 Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East 
respiratory syndrome coronavirus. N Engl  J Med 2013; 369: 407–16.
7 Cotten M, Watson SJ, Kellam P, et al. Transmission and evolution of the 
Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive 
genomic study. Lancet 2013; published online Sept 20. http://dx.doi.
org/10.1016/S0140-6736(13)61887-5.
8 Penttinen PM, Kaasik-Aaslav K, Friaux A, et al. Taking stock of the fi rst 
133 MERS coronavirus cases globally—is the epidemic changing? 
Euro Surveill 2013; 18: 20596.
9 Breban R, Riou J, Fontanet A. Interhuman transmissibility of Middle East 
respiratory syndrome coronavirus: estimation of pandemic risk. 
Lancet 2013; 382: 694–99.
10 WHO. WHO statement on the third meeting of the IHR Emergency 
Committee concerning MERS-CoV. http://www.who.int/mediacentre/
news/statements/2013/mers_cov_20130925/en/index.html (accessed 
Nov 29, 2013).
11 Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin 
infl uenza A (H7N9) virus. N Engl J Med 2013; 368: 1888–97.
12 Chen Y, Liang W, Yang S, et al. Human infections with the emerging avian 
infl uenza A H7N9 virus from wet market poultry: clinical analysis and 
characterization of viral genome. Lancet 2013; 381: 1916–25.
13 WHO. Number of confi rmed human cases of avian infl uenza A(H7N9) 
reported to WHO. Report 9—data in WHO/HQ as of 12 August 2013, 
14:45 GMT+1. http://www.who.int/infl uenza/human_animal_interface/
infl uenza_h7n9/09_ReportWebH7N9Number.pdf (accessed Nov 18, 2013).
14 Gao HN, Lu HZ, Cao B, et al. Clinical fi ndings in 111 cases of infl uenza A 
(H7N9) virus infection. N Engl J Med 2013; 368: 2277–85.
15 Dudley JP, Mackay IM. Age-specifi c and sex-specifi c morbidity and mortality 
from avian infl uenza A(H7N9). J Clin Virol 2013; 58: 568–70.
Published Online
December 23, 2013
http://dx.doi.org/10.1016/
S2213-2600(13)70256-X
Tuberculosis: progress and challenges in product 
development and delivery
Although global tuberculosis control is improving, 
pro gress remains slow; about 1·3 million people 
died of tuberculosis in 2012, more deaths than from 
any other single infectious agent (other than HIV).1 
WHO emphasised two major challenges in 2013: 
identifying and treating the “missing 3 million” 
people who develop active tuberculosis every year and 
whose condition never becomes known to national 
tuberculosis control programmes; and the crisis of 
multidrug-resistant (MDR) tuberculosis, in which 
three of four people with MDR tuberculosis are never 
diagnosed, and less than half of those diagnosed are 
successfully treated.1
New diagnostics, drugs, and vaccines are crucial 
for transformational progress. 2013 heralded both 
progress and disappointment in these areas. In 
diagnostics, progress was made in the global scale-up 
of Xpert MTB/RIF (Cepheid Inc, Sunnyvale, CA, USA), 
a molecular test for tuberculosis that also enables 
rapid detection of resistance to rifampicin. More than 
4 million MTB/RIF cartridges had been procured under 
concessional pricing as of September, 2013, and a 
US$25·9 million UNITAID project was announced in 
March, 2013, for rollout in 21 countries.2 Based on new 
evidence, WHO recommended in October, 2013, that 
Xpert MTB/RIF be used as the initial diagnostic test in 
adults and children with presumed MDR tuberculosis or 
HIV-associated tuberculosis (and, conditionally, for all 
forms of tuberculosis), as well as for diagnosis of certain 
types of extrapulmonary tuberculosis.3 
The fi rst randomised trial of Xpert MTB/RIF was 
published in October, 2013.4 This pragmatic, multicentre 
trial of nurse-led Xpert MTB/RIF versus sputum-smear 
microscopy in people with symptoms of tuberculosis 
presenting to primary care clinics in four African 
countries showed Xpert MTB/RIF to be more accurate 
than smears and more eff ective in leading to same-day 
treatment initiation. However, the primary outcome of 
tuberculosis-related morbidity was equivalent between 
the two arms, as was treatment initiation by 56 days.4 
The authors postulated that this lack of diff erence in 
morbidity was the result of high empirical treatment 
rates among smear-negative individuals with ongoing 
symptoms. Results from additional trials in Brazil and 
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